A Phase I Trial of Nifurtimox for Relapsed or Refractory Neuroblastoma
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Test the safety of nifurtimox in children with relapsed or refractory neuroblastoma alone and in combination with cyclophosphamide and topotecan.
Giselle Sholler, MD
University of Vermont / Vermont Children's Hospital
United States: Food and Drug Administration
|St. Louis University/Cardinal Glennon Childrens Medical Center||St. Louis, Missouri 63104|
|University of Vermont/Vermont Children's Hospital||Burlington, Vermont 05401|